Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XH001 and Sintilimab in Advanced Solid Tumors
NCT05940181Phase 1Recruiting
- Start
- Mar 2023
- Primary completion
- May 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PGV002 in solid tumor. Primary endpoints: Maximum Tolerated Dose or Clinical Recommended Dose at 6 months, Dose-Limiting Toxicity at 21 days and 1 more. Started Mar 2023; status: recruiting.
02
Drugs
PGV002
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05940181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05940181.